Modulation of plasmacytoid dendritic cell function in multiple sclerosis
Phase of Trial: Phase IV
Latest Information Update: 26 May 2017
At a glance
- Drugs Interferon beta-1b (Primary)
- Indications Multiple sclerosis
- Focus Pharmacodynamics; Pharmacogenomic
- 12 Sep 2011 Planned end date changed from 1 Dec 2010 to 1 Dec 2011 as reported by ClinicalTrials.gov.
- 25 Jun 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 09 Jun 2008 Bayer reported as trial sponsor by ClinicalTrials.gov